aFGF immunoreactivity in prostate cancer and its co-localization with bFGF and FGF8
- PMID: 10629559
- DOI: 10.1002/(SICI)1096-9896(199912)189:4<564::AID-PATH480>3.0.CO;2-1
aFGF immunoreactivity in prostate cancer and its co-localization with bFGF and FGF8
Abstract
Fibroblast growth factors (FGFs) have been implicated in the development of numerous malignancies including prostate cancer. In a pilot study it has been shown that FGF8 mRNA is up-regulated in prostate cancer. The aim of the present study was to determine whether aFGF and bFGF were co-expressed with FGF8 in human prostate cancer. Twenty-nine cases of prostate cancer of different histological grades were examined. Immunohistochemical analysis was employed to study aFGF and bFGF expression. In the light of the results, aFGF immunoreactivity was studied in a further 43 cases. aFGF and bFGF immunoreactivity was identified in the cytoplasm of the malignant prostatic epithelium. aFGF was overexpressed in 62/72 (86.1 per cent) cases and bFGF in 19/29 (65.5 per cent). High levels of aFGF immunoreactivity were noted in areas of high-grade prostatic intraepithelial neoplasia (PIN). In this series, aFGF immunoreactivity was most commonly observed and correlated closely with Gleason score and tumour stage ( p=0.007 and 0.007, respectively). Co-localization of aFGF, bFGF, and FGF8 was detected in 9/29 (31.0 per cent) cases. There was a significant correlation between aFGF and FGF8 expression. In conclusion, aFGF, bFGF, and FGF8 are co-localized in human prostate cancer; they may have a synergistic effect in prostate cancer growth and progression.
Copyright 1999 John Wiley & Sons, Ltd.
Similar articles
-
Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage.Cancer Res. 1993 Nov 1;53(21):5289-96. Cancer Res. 1993. PMID: 7693336
-
Fibroblast growth factor 17 is over-expressed in human prostate cancer.J Pathol. 2004 Dec;204(5):578-86. doi: 10.1002/path.1668. J Pathol. 2004. PMID: 15538740
-
FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease.Oncogene. 1999 Apr 29;18(17):2755-61. doi: 10.1038/sj.onc.1202624. Oncogene. 1999. PMID: 10348350
-
[Fibroblast growth factors (FGFs) in neurodegenerative disorders].Rinsho Shinkeigaku. 1993 Dec;33(12):1270-4. Rinsho Shinkeigaku. 1993. PMID: 8174323 Review. Japanese.
-
Angiogenesis in the adult heart.Basic Res Cardiol. 1991;86 Suppl 2:51-6. doi: 10.1007/978-3-642-72461-9_6. Basic Res Cardiol. 1991. PMID: 1719953 Review.
Cited by
-
Current status and perspective of antiangiogenic therapy for cancer: urinary cancer.Int J Clin Oncol. 2006 Apr;11(2):90-107. doi: 10.1007/s10147-006-0565-6. Int J Clin Oncol. 2006. PMID: 16622744 Review.
-
Activin receptor signaling regulates prostatic epithelial cell adhesion and viability.Neoplasia. 2009 Apr;11(4):365-76. doi: 10.1593/neo.81544. Neoplasia. 2009. PMID: 19308291 Free PMC article.
-
Notch signaling modulates hypoxia-induced neuroendocrine differentiation of human prostate cancer cells.Mol Cancer Res. 2012 Feb;10(2):230-8. doi: 10.1158/1541-7786.MCR-11-0296. Epub 2011 Dec 15. Mol Cancer Res. 2012. PMID: 22172337 Free PMC article.
-
Mitochondrial DNA mutation stimulates prostate cancer growth in bone stromal environment.Prostate. 2009 Jan 1;69(1):1-11. doi: 10.1002/pros.20854. Prostate. 2009. PMID: 18850577 Free PMC article.
-
Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer.Br J Cancer. 2001 Aug 17;85(4):576-83. doi: 10.1054/bjoc.2001.1971. Br J Cancer. 2001. PMID: 11506499 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
